Researcher profile

Hamidreza Badri

Hamidreza Badri contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 13 - UnverifiedVerification L1Unclaimed author
2works
0followers
3topics
3close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2015arXiv

Minimizing Metastatic Risk in Radiotherapy Fractionation Schedules

Metastasis is the process by which cells from a primary tumor disperse and form new tumors at distant anatomical locations. The treatment and prevention of metastatic cancer remains an extremely challenging problem. This work introduces a novel biologically motivated objective function to the radiation optimization community that takes into account metastatic risk instead of the status of the primary tumor. In this work, we consider the problem of developing fractionated irradiation schedules that minimize production of metastatic cancer cells while keeping normal tissue damage below an acceptable level. A dynamic programming framework is utilized to determine the optimal fractionation scheme. We evaluated our approach on a breast cancer case using the heart and the lung as organs-at-risk (OAR). For small tumor $α/β$ values, hypo-fractionated schedules were optimal, which is consistent with standard models. However, for relatively larger $α/β$ values, we found the type of schedule depended on various parameters such as the time when metastatic risk was evaluated, the $α/β$ values of the OARs, and the normal tissue sparing factors. Interestingly, in contrast to standard models, hypo-fractionated and semi-hypo-fractionated schedules (large initial doses with doses tapering off with time) were suggested even with large tumor $α$/$β$ values. Numerical results indicate potential for significant reduction in metastatic risk.

preprint2015arXiv

Robust and probabilistic optimization of dose schedules in radiotherapy

We consider the effects of parameter uncertainty on the optimal radiation schedule in the context of the linear-quadratic model. Our interest arises from the observation that if inter-patient variations in OAR and tumor sensitivities to radiation or sparing factor of the OAR are not accounted for during radiation scheduling, the performance of the therapy may be strongly degraded or the OAR may receive a substantially larger dose than the maximum threshold. This paper proposes two radiation scheduling concepts to incorporate inter-patient variability into the scheduling optimization problem. The first approach is a robust formulation that formulates the problem as a conservative model that optimizes the worst case dose scheduling that may occur. The second method is a probabilistic approach, where the model parameters are given by a set of random variables. This formulation insures that our constraints are satisfied with a given probability, and that our objective function achieves a desired level with a stated probability. We used a transformation to reduce the resulting optimization problem to two dimensions. We showed that the optimal solution lies on the boundary of the feasible region and we used a branch and bound algorithm to find the global optimal solution. We observed that if the number of fractions in the optimal conventional schedule is the same as the robust and stochastic solutions, it is preferable to administer equal or smaller total dose. In addition if there exist more (fewer) treatment sessions in the probabilistic or robust solution compared to the conventional schedule, a reduction in total dose squared (total dose) will be expected. Finally, we performed numerical experiments in the setting of head-and-neck tumors to reveal the effect of parameter uncertainty on optimal schedules and to evaluate the sensitivity of the model to the choice of key model parameters.